Hims & Hers Stock Soars on Strategic Pivot with Novo Nordisk

Hims & Hers abandons compounding for a direct Novo Nordisk deal, restoring access to Wegovy and sending its stock soaring nearly 40% in after-hours trading.

A significant strategic shift is underway at Hims & Hers Health, marked by a newly announced long-term partnership with pharmaceutical giant Novo Nordisk. The agreement resolves a prior legal dispute and restores the telehealth company's access to Novo's branded GLP-1 weight-loss medications, signaling a decisive move away from its controversial compounding business.

Market Reaction Validates Strategic Shift

The financial markets delivered a swift and powerful verdict on the news. In after-hours trading, shares of Hims & Hers skyrocketed by 39.77% to $22. This surge followed a regular Friday session close at $15.74, down 0.88%. Novo Nordisk's stock also saw positive movement, climbing 2.12% to $39.40 in extended trading after closing at $38.58, down 1.25%.

This dramatic revaluation reflects the resolution of weeks of mounting pressure from legal and regulatory challenges. The new deal replaces market speculation with concrete commercial terms, including a defined price structure, providing investors with greater certainty.

Partnership Details: Bundled Access to Wegovy

The cornerstone of the collaboration is a bundled offering for U.S. customers. They will gain direct access to the NovoCare® Pharmacy through the Hims platform. The package includes Wegovy® (across all dosage strengths) paired with a Hims membership, which provides round-the-clock support, ongoing clinical oversight, and nutritional guidance.

The companies announced a unified monthly package price starting at $599. Furthermore, they are developing a joint "roadmap" aimed at scaling Novo Nordisk's therapies through Hims' digital infrastructure, with the long-term objective of broadening access and reducing treatment costs.

From Conflict to Alliance: Abandoning the Compounding Model

This agreement represents a second attempt at collaboration between the two firms. A previous partnership announced in April was terminated by Novo Nordisk in June, citing safety concerns over compounding products offered by Hims. Despite the breakup, Hims continued to market compounded alternatives.

Tensions escalated last month when Novo Nordisk filed a patent infringement lawsuit. The legal action was triggered by Hims' launch of a $49 compounding pill designed to mimic Novo's proprietary formulation. Hims subsequently withdrew the product under pressure from the U.S. Food and Drug Administration (FDA). The FDA had separately issued warnings about potential enforcement actions against the sale of compounded semaglutid, the active ingredient in Wegovy and Ozempic.

From its peak, Hims & Hers stock had plummeted by 77%. The new partnership explicitly marks a departure from the compounding strategy, transitioning its weight-loss offerings to branded therapies. While this may reduce legal overhang, it also creates a deeper operational dependency on Novo Nordisk for supply, regulatory compliance, and distribution.

Financial Foundation and Concurrent Expansion

Hims & Hers reported strong financial results for 2025, with revenue of $2.35 billion (a 59% year-over-year increase), net income of $128.4 million, and an adjusted EBITDA of $318.0 million. The company's subscriber base exceeded 2.5 million.

Looking ahead to 2026, management had previously provided guidance forecasting revenue between $2.7 billion and $2.9 billion, alongside an adjusted EBITDA of $300 million to $375 million. It is important to note that this outlook was issued prior to the newly announced GLP-1 deal.

In a separate major strategic move, Hims & Hers announced in late February its agreement to acquire Eucalyptus in a transaction valued at up to $1.15 billion. Eucalyptus operates in Australia, the United Kingdom, and Germany, and is expanding its presence in Japan and Canada. This acquisition is expected to be finalized by mid-2026.

The day's developments underscore one clear conclusion for investors: the market perceives the return to a legitimate Wegovy supply as a critical turning point. The deal can now be evaluated based on tangible commercial terms like the $599 bundle, moving beyond vague expectations to measurable metrics.